1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models

IF 5.9 2区 医学 Q1 CHEMISTRY, MEDICINAL
Yi Zou, Shushan Ge, Haiqing Zhong, Yingbo Zheng, Xuewei Ma, Wenbin Liu, Fang Wang, Wenjie Guo, Wen Liu, Qiang Xu, Yisheng Lai
{"title":"1-(3,4-Diaminophenyl)-1H-pyrrole-2-carboxylic acids as potent apo-IDO1 inhibitors exhibiting efficacy in syngeneic tumor mouse models","authors":"Yi Zou, Shushan Ge, Haiqing Zhong, Yingbo Zheng, Xuewei Ma, Wenbin Liu, Fang Wang, Wenjie Guo, Wen Liu, Qiang Xu, Yisheng Lai","doi":"10.1016/j.ejmech.2025.118222","DOIUrl":null,"url":null,"abstract":"Indolamine 2,3-dioxygenase 1 (IDO1)-mediated kynurenine pathway has been identified as an important immune escape mechanism in cancer, and pharmacological inhibition of IDO1 is regarded as a potential strategy for cancer treatment. Herein, we describe the identification of novel 1<em>H</em>-pyrrole-2-carboxylic acid-based IDO1 inhibitors targeting its apo form with picomolar potency in the HeLa cell-based assay. Among them, compound <strong>45</strong> showed the strongest inhibitory activity against IDO1 with an IC<sub>50</sub> value of 10 pM. Notably, oral administration of <strong>45</strong> at 10 mg/kg significantly suppressed tumor growth by activating antitumor immunity without significant toxicity in a CT26 syngeneic mouse model. Furthermore, the tumor burden could similarly be decreased in an LLC syngeneic mouse model treated with <strong>45</strong>, indicating the potential of <strong>45</strong> for the treatment of distinct tumor types. Collectively, these data suggest that compound <strong>45</strong> may be used as a promising lead compound for further investigation.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"157 1","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.118222","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Indolamine 2,3-dioxygenase 1 (IDO1)-mediated kynurenine pathway has been identified as an important immune escape mechanism in cancer, and pharmacological inhibition of IDO1 is regarded as a potential strategy for cancer treatment. Herein, we describe the identification of novel 1H-pyrrole-2-carboxylic acid-based IDO1 inhibitors targeting its apo form with picomolar potency in the HeLa cell-based assay. Among them, compound 45 showed the strongest inhibitory activity against IDO1 with an IC50 value of 10 pM. Notably, oral administration of 45 at 10 mg/kg significantly suppressed tumor growth by activating antitumor immunity without significant toxicity in a CT26 syngeneic mouse model. Furthermore, the tumor burden could similarly be decreased in an LLC syngeneic mouse model treated with 45, indicating the potential of 45 for the treatment of distinct tumor types. Collectively, these data suggest that compound 45 may be used as a promising lead compound for further investigation.

Abstract Image

1-(3,4-二氨基苯基)- 1h -吡咯-2-羧酸是有效的载脂蛋白ido1抑制剂,在同基因肿瘤小鼠模型中显示有效
吲哚胺2,3-双加氧酶1 (IDO1)介导的犬尿氨酸途径已被确定为癌症中重要的免疫逃逸机制,药物抑制IDO1被认为是治疗癌症的潜在策略。在这里,我们描述了在HeLa细胞为基础的实验中,鉴定了一种新的以1h -吡咯-2-羧酸为基础的IDO1抑制剂,该抑制剂靶向其载脂蛋白形式,具有皮摩尔效力。其中化合物45对IDO1的抑制活性最强,IC50值为10 pM。值得注意的是,在CT26同基因小鼠模型中,口服45 (10 mg/kg)通过激活抗肿瘤免疫显著抑制肿瘤生长,且无明显毒性。此外,在45处理的LLC同基因小鼠模型中,肿瘤负荷同样可以减少,这表明45治疗不同类型肿瘤的潜力。综上所述,这些数据表明化合物45可能作为一种有前途的先导化合物进行进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信